Companies › Bazelet Nehushtan
1 active drug program in 2 registered trials: 2 Phase 2; Psychiatry; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Terpenes-Enriched CBD-Predominant Oil (T1/C28) Cannabinoid system modulation with CBD and minor THC with terpenes | CNR1, CNR2 | Phase 2 | Autism | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07199218 | Terpenes-Enriched CBD-Predominant Oil (T1/C28) | Phase 2 | Autism | Psychiatry | Dec 2027 |
| NCT07199218 | Terpenes-Enriched CBD-Predominant Oil (T1/C28) | Phase 2 | Autism | Psychiatry | Dec 2027 |
IGC Pharma Zynerba Pharmaceuticals Incannex Healthcare Vertanical Alasht Pharmed Jazz Pharmaceuticals Sinfatin Skye Bioscience PleoPharma Laboratorio Elea Phoenix
PleoPharma NeuroRx Autobahn Therapeutics atai Therapeutics Arialys Australia
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.